Exvastat
Cambridge
About Exvastat
Exvastat is an innovative, preclinical-stage pharmaceutical company founded in 2016. The company is developing a treatment for acute respiratory distress syndrome (ARDS) based on a repurposed drug which is marketed worldwide for other indications. The new treatment has the potential to significantly reduce the high mortality and incapacitating morbidities caused by ARDS, as well as the costs of caring for these critically ill patients to health service providers.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $3.9M
- Funding stage: Seed
- Last round: Grant (May 2020)
- Website: exvastat.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Life Science, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/exvastat-101292 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.